DK2261380T3 - Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA vira med klasse I membranfusogene indhyldningsproteiner - Google Patents

Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA vira med klasse I membranfusogene indhyldningsproteiner

Info

Publication number: DK2261380T3
Authority: DK; Denmark
Prior art keywords: fusion; virus; present; viruses; class
Prior art date: 2003-11-04

Application number

DK10182060.3T

Other languages

English (en)

Inventor

Robert F Garry

Russell B Wilson

Original Assignee

Univ Tulane

Autoimmune Technologies Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-04

Filing date

2004-11-03

Publication date

2013-10-07

2004-11-03 Application filed by Univ Tulane, Autoimmune Technologies Llc filed Critical Univ Tulane

2013-10-07 Application granted granted Critical

2013-10-07 Publication of DK2261380T3 publication Critical patent/DK2261380T3/da

Links

238000000034 method Methods 0.000 title abstract 5
230000004927 fusion Effects 0.000 title abstract 3
241001493065 dsRNA viruses Species 0.000 title abstract 2
230000002401 inhibitory effect Effects 0.000 title abstract 2
230000000977 initiatory effect Effects 0.000 title abstract 2
239000012528 membrane Substances 0.000 title abstract 2
101710091045 Envelope protein Proteins 0.000 title 1
101710188315 Protein X Proteins 0.000 title 1
102100021696 Syncytin-1 Human genes 0.000 title 1
230000007910 cell fusion Effects 0.000 title 1
230000000799 fusogenic effect Effects 0.000 title 1
241000700605 Viruses Species 0.000 abstract 5
208000036142 Viral infection Diseases 0.000 abstract 2
210000004027 cell Anatomy 0.000 abstract 2
230000009385 viral infection Effects 0.000 abstract 2
241000712891 Arenavirus Species 0.000 abstract 1
241000711573 Coronaviridae Species 0.000 abstract 1
241000711950 Filoviridae Species 0.000 abstract 1
102000018897 Membrane Fusion Proteins Human genes 0.000 abstract 1
108010027796 Membrane Fusion Proteins Proteins 0.000 abstract 1
210000000805 cytoplasm Anatomy 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
238000007499 fusion processing Methods 0.000 abstract 1
102000037865 fusion proteins Human genes 0.000 abstract 1
108020001507 fusion proteins Proteins 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000002452 interceptive effect Effects 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1
241001430294 unidentified retrovirus Species 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18433—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Virology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Wood Science & Technology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Engineering & Computer Science (AREA)
AIDS & HIV (AREA)
Cell Biology (AREA)
Pathology (AREA)
Toxicology (AREA)
General Physics & Mathematics (AREA)
Tropical Medicine & Parasitology (AREA)
Food Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)

DK10182060.3T 2003-11-04 2004-11-03 Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA vira med klasse I membranfusogene indhyldningsproteiner DK2261380T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US51718103P	2003-11-04	2003-11-04
EP04810256A EP1692265B1 (en)	2003-11-04	2004-11-03	Method of preventing virus: cell fusion by inhibiting the function of the fusion initiation region in rna viruses having class i membrane fusogenic envelope proteins

Publications (1)

Publication Number	Publication Date
DK2261380T3 true DK2261380T3 (da)	2013-10-07

Family

ID=34572923

Family Applications (7)

Application Number	Title	Priority Date	Filing Date
DK10182040.5T DK2261376T3 (da)	2003-11-04	2004-11-03	Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA vira med klasse I membranfusogene indhyldningsproteiner
DK10181974.6T DK2261374T3 (da)	2003-11-04	2004-11-03	Fremgangsmåde til hæmning af viruscellefusion ved hæmning af fusionsstartområdets funktion i RNA-virus med klasse 1 membran-fusiogene indhyllings-proteiner
DK04810256.0T DK1692265T3 (da)	2003-11-04	2004-11-03	Fremgangsmåde til hindring af en virus-celle-fusion ved hæmning af fusionsinitieringsområdets funktion i RNA-vira med klasse 1-membranfusogene envelopeproteiner
DK10182049.6T DK2261377T3 (da)	2003-11-04	2004-11-03	Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA virus med klasse I membran-fusogene kappeproteiner
DK10182060.3T DK2261380T3 (da)	2003-11-04	2004-11-03	Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA vira med klasse I membranfusogene indhyldningsproteiner
DK10182018.1T DK2261375T3 (da)	2003-11-04	2004-11-03	Fremgangsmåde til hindring af viruscellefusion ved hæmning af funktionen af fusionsinitieringsområdet i RNA-vira med klasse I membranfusogene kappeproteiner
DK10182056.1T DK2261378T3 (da)	2003-11-04	2004-11-03	Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA virus med klasse I membranfusogene kappeproteiner

Family Applications Before (4)

Application Number	Title	Priority Date	Filing Date
DK10182040.5T DK2261376T3 (da)	2003-11-04	2004-11-03	Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA vira med klasse I membranfusogene indhyldningsproteiner
DK10181974.6T DK2261374T3 (da)	2003-11-04	2004-11-03	Fremgangsmåde til hæmning af viruscellefusion ved hæmning af fusionsstartområdets funktion i RNA-virus med klasse 1 membran-fusiogene indhyllings-proteiner
DK04810256.0T DK1692265T3 (da)	2003-11-04	2004-11-03	Fremgangsmåde til hindring af en virus-celle-fusion ved hæmning af fusionsinitieringsområdets funktion i RNA-vira med klasse 1-membranfusogene envelopeproteiner
DK10182049.6T DK2261377T3 (da)	2003-11-04	2004-11-03	Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA virus med klasse I membran-fusogene kappeproteiner

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK10182018.1T DK2261375T3 (da)	2003-11-04	2004-11-03	Fremgangsmåde til hindring af viruscellefusion ved hæmning af funktionen af fusionsinitieringsområdet i RNA-vira med klasse I membranfusogene kappeproteiner
DK10182056.1T DK2261378T3 (da)	2003-11-04	2004-11-03	Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA virus med klasse I membranfusogene kappeproteiner

Country Status (12)

Country	Link
US (5)	US7491793B2 (da)
EP (7)	EP2261380B1 (da)
JP (1)	JP5008398B2 (da)
AT (1)	ATE518967T1 (da)
AU (2)	AU2004288218B2 (da)
BR (1)	BRPI0416187A (da)
CA (1)	CA2544848C (da)
DK (7)	DK2261376T3 (da)
ES (7)	ES2437858T3 (da)
PL (4)	PL1692265T3 (da)
PT (4)	PT2261378E (da)
WO (1)	WO2005044992A2 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL1692265T3 (pl)	2003-11-04	2011-12-30	The Administrators Of The Tulane Educational Fund	Sposób zapobiegania fuzji wirus:komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I
US7682619B2 (en)	2006-04-06	2010-03-23	Cornell Research Foundation, Inc.	Canine influenza virus
US8222204B2 (en) *	2006-05-03	2012-07-17	The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC	Influenza inhibiting compositions and methods
KR20160113331A (ko) *	2007-06-25	2016-09-28	더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드	인플루엔자를 억제하는 조성물 및 방법
WO2009005783A1 (en) *	2007-06-28	2009-01-08	Blanchette Rockefeller Neurosciences Institute	Peptides, compositions and methods for reducing beta-amyloid-mediated apoptosis
CA2735278A1 (en) *	2008-08-28	2010-03-04	Aarhus Universitet	Hiv-1 envelope polypeptides for hiv vaccine
WO2010117786A1 (en)	2009-03-30	2010-10-14	Mount Sinai School Of Medicine Of New York University	Influenza virus vaccines and uses thereof
US10138276B2 (en) *	2009-09-30	2018-11-27	Signablok, Inc.	Inhibition of TCR signaling with peptide variants
US20130108653A1 (en) *	2009-12-22	2013-05-02	Shervin Bahrami	Bivalent molecules for hiv entry inhibition
WO2011094363A2 (en)	2010-01-26	2011-08-04	The Regents Of The University Of Colorado	Influenza virus compositions and methods for universal vaccines
CN102939096B (zh) *	2010-02-18	2016-03-02	西奈山医学院	用于预防和治疗流感病毒疾病的疫苗
WO2011123495A1 (en)	2010-03-30	2011-10-06	Mount Sinai School Of Medicine	Influenza virus vaccines and uses thereof
US20130289246A1 (en) *	2010-09-30	2013-10-31	Vanderbilt University	Influenza virus antibodies and immunogens and uses therefor
US9060972B2 (en) *	2010-10-30	2015-06-23	George Dacai Liu	Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
ES2953393T3 (es)	2011-09-20	2023-11-10	Icahn School Med Mount Sinai	Vacunas contra el virus de la influenza y sus usos
US9969794B2 (en)	2012-05-10	2018-05-15	Visterra, Inc.	HA binding agents
SG11201504728RA (en)	2012-12-18	2015-07-30	Icahn School Med Mount Sinai	Influenza virus vaccines and uses thereof
US8999925B2 (en) *	2013-02-26	2015-04-07	The Administrators Of The Tulane Educational Fund	Arenavirus inhibiting peptides and uses therefor
WO2014159960A1 (en)	2013-03-14	2014-10-02	Icahn School Of Medicine At Mount Sinai	Antibodies against influenza virus hemagglutinin and uses thereof
US9649375B2 (en) *	2013-03-14	2017-05-16	The Administrators Of The Tulane Educational Fund	Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
WO2016049380A1 (en) *	2014-09-24	2016-03-31	University Of Utah Research Foundation	Ebolavirus pre-hairpin intermediate mimics and methods of use
US10736956B2 (en)	2015-01-23	2020-08-11	Icahn School Of Medicine At Mount Sinai	Influenza virus vaccination regimens
US10513553B2 (en)	2015-11-13	2019-12-24	Visterra, Inc.	Compositions and methods for treating and preventing influenza
EP3419663A1 (en)	2016-02-24	2019-01-02	Visterra, Inc.	Formulations of antibody molecules to influenza virus
US11266734B2 (en)	2016-06-15	2022-03-08	Icahn School Of Medicine At Mount Sinai	Influenza virus hemagglutinin proteins and uses thereof
EP3606555A4 (en)	2017-04-07	2021-08-04	Icahn School of Medicine at Mount Sinai	INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
US11690907B2 (en)	2018-06-12	2023-07-04	Kbio Holdings Limited	Vaccines formed by virus and antigen conjugation
US11696948B2 (en)	2018-06-12	2023-07-11	Kbio Holdings Limited	Vaccines formed by virus and antigen conjugation
EP3810634A4 (en)	2018-06-21	2022-07-27	Icahn School of Medicine at Mount Sinai	Mosaic influenza virus hemagglutinin polypeptides and uses thereof
JP2022521819A (ja)	2019-03-25	2022-04-12	ビステラ，インコーポレイテッド	インフルエンザを処置および予防するための組成物および方法
US12545718B2 (en)	2019-04-24	2026-02-10	Icahn School Of Medicine At Mount Sinai	Anti-influenza B virus neuraminidase antibodies and uses thereof
US20230014151A1 (en) *	2019-09-04	2023-01-19	The Trustees Of Columbia University In The City Of New York	Combination antiviral therapy for measles
US11479582B2 (en)	2020-10-16	2022-10-25	King Faisal University	Anti-SARS-CoV-2 fusion peptides
JP7598538B2 (ja) *	2021-01-29	2024-12-12	東亞合成株式会社	ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用
AU2022249423A1 (en) *	2021-03-30	2023-11-09	Baylor College Of Medicine	Methods and compositions for high-potency polypeptide-based protein inhibition

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1711888A (en) *	1987-04-24	1988-12-02	Biogen, Inc.	Immunotherapeutic methods and compositions
US5747239A (en)	1990-02-16	1998-05-05	United Biomedical, Inc.	Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US5567805A (en)	1990-03-09	1996-10-22	Administrators Of The Tulane Educational Fund	The cellular receptor for the CS3 peptide of human immunodeficiency virus
WO1994017826A1 (en) *	1993-02-01	1994-08-18	Smithkline Beecham Corporation	Vaccinal polypeptides
US5464933A (en)	1993-06-07	1995-11-07	Duke University	Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) *	1993-06-07	2002-11-12	Trimeris, Inc.	Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6037348A (en)	1996-02-09	2000-03-14	Eli Lilly And Company	Inhibition of viral replication
JPH11209281A (ja) *	1998-01-21	1999-08-03	Daikin Ind Ltd	ヘマグルチニン結合活性及びシアリダーゼ活性に対する阻害剤、及び、これを用いてウイルス又は微生物の感染を治療及び／又は予防する方法
IL127331A0 (en)	1998-11-30	1999-09-22	Yeda Res & Dev	Peptide-based vaccine for influenza
CA2365575A1 (en) *	1999-03-31	2000-10-12	Otsuka Pharmaceutical Co., Ltd.	Influenza virus hemagglutinin-binding peptides
US6750008B1 (en)	1999-07-09	2004-06-15	Trimeris, Inc.	Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
AU7089600A (en) *	1999-08-30	2001-03-26	U.S. Army Medical Research Institute Of Infectious Diseases	Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
NZ520754A (en) *	2000-02-10	2004-02-27	Panacos Pharmaceuticals Inc	Identifying compounds that disrupt formation of critical gp41 six-helix bundle and conformations necessary for HIV entry thereby blocking virus entry to the cell
GB0022969D0 (en)	2000-09-19	2000-11-01	Chiron Spa	Influenza a virus subtype H16
EP1353942B1 (en) *	2000-09-22	2010-12-15	Whitehead Institute For Biomedical Research	Peptide inhibitors of hiv entry
WO2002079239A2 (en) *	2001-01-31	2002-10-10	U.S. Army Medical Research Institute Of Infectious Diseases	Chimeric filovirus glycoprotein
US7442761B2 (en) *	2003-06-06	2008-10-28	Samuel Bogoch	Replikin peptides and uses thereof
US7452963B2 (en) *	2001-03-27	2008-11-18	Samuel Bogoch	Replikin peptides and antibodies therefore
US7774144B2 (en) *	2001-10-26	2010-08-10	Samuel Bogoch	System and method for identifying complex patterns of amino acids
US7189800B2 (en) *	2001-03-27	2007-03-13	Samuel Bogoch	Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7420028B2 (en) *	2001-03-27	2008-09-02	Samuel Bogoch	Replikins and methods of identifying replikin-containing sequences
NZ592340A (en) *	2001-03-27	2012-12-21	Elenore S Bogoch	A method for making a virus vaccine compising Replikin peptides
JP4651213B2 (ja) *	2001-03-27	2011-03-16	株式会社グライコメディクス	インフルエンザウイルス・ヘマグルチニン結合性ペプチド
US7894999B2 (en) *	2001-03-27	2011-02-22	Samuel Bogoch	Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
AU2003245729A1 (en) *	2002-06-27	2004-01-19	Dana-Farber Cancer Institute, Inc.	Compositions and methods for modulating a cytotoxic t lymphocyte immune response
WO2005016238A2 (en) *	2003-05-08	2005-02-24	Duke University	Severe acute respiratory syndrome
WO2004111081A2 (en) *	2003-06-13	2004-12-23	Crucell Holland B.V.	Antigenic peptides of sars coronavirus and uses thereof
TW200510450A (en) *	2003-07-21	2005-03-16	Nat Inst Health	Soluble fragments of the SARS-CoV spike glycoprotein
PL1692265T3 (pl)	2003-11-04	2011-12-30	The Administrators Of The Tulane Educational Fund	Sposób zapobiegania fuzji wirus:komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I

2004
- 2004-11-03 PL PL04810256T patent/PL1692265T3/pl unknown
- 2004-11-03 DK DK10182040.5T patent/DK2261376T3/da active
- 2004-11-03 DK DK10181974.6T patent/DK2261374T3/da active
- 2004-11-03 EP EP10182060.3A patent/EP2261380B1/en not_active Expired - Lifetime
- 2004-11-03 AU AU2004288218A patent/AU2004288218B2/en not_active Ceased
- 2004-11-03 ES ES10182056.1T patent/ES2437858T3/es not_active Expired - Lifetime
- 2004-11-03 US US10/578,013 patent/US7491793B2/en not_active Expired - Lifetime
- 2004-11-03 DK DK04810256.0T patent/DK1692265T3/da active
- 2004-11-03 AT AT04810256T patent/ATE518967T1/de active
- 2004-11-03 PT PT101820561T patent/PT2261378E/pt unknown
- 2004-11-03 PL PL10182049T patent/PL2261377T3/pl unknown
- 2004-11-03 EP EP10182049.6A patent/EP2261377B1/en not_active Expired - Lifetime
- 2004-11-03 DK DK10182049.6T patent/DK2261377T3/da active
- 2004-11-03 PT PT101820496T patent/PT2261377E/pt unknown
- 2004-11-03 WO PCT/US2004/036578 patent/WO2005044992A2/en not_active Ceased
- 2004-11-03 ES ES10182040T patent/ES2425600T3/es not_active Expired - Lifetime
- 2004-11-03 ES ES10182049T patent/ES2435941T3/es not_active Expired - Lifetime
- 2004-11-03 PT PT101820405T patent/PT2261376E/pt unknown
- 2004-11-03 EP EP10182056.1A patent/EP2261378B1/en not_active Expired - Lifetime
- 2004-11-03 JP JP2006538450A patent/JP5008398B2/ja not_active Expired - Fee Related
- 2004-11-03 ES ES04810256T patent/ES2372633T3/es not_active Expired - Lifetime
- 2004-11-03 DK DK10182060.3T patent/DK2261380T3/da active
- 2004-11-03 EP EP10182040.5A patent/EP2261376B1/en not_active Expired - Lifetime
- 2004-11-03 EP EP10182018A patent/EP2261375B1/en not_active Expired - Lifetime
- 2004-11-03 EP EP04810256A patent/EP1692265B1/en not_active Expired - Lifetime
- 2004-11-03 DK DK10182018.1T patent/DK2261375T3/da active
- 2004-11-03 DK DK10182056.1T patent/DK2261378T3/da active
- 2004-11-03 PT PT04810256T patent/PT1692265E/pt unknown
- 2004-11-03 ES ES10181974T patent/ES2392891T3/es not_active Expired - Lifetime
- 2004-11-03 ES ES10182060T patent/ES2427847T3/es not_active Expired - Lifetime
- 2004-11-03 PL PL10182040T patent/PL2261376T3/pl unknown
- 2004-11-03 BR BRPI0416187-4A patent/BRPI0416187A/pt not_active Application Discontinuation
- 2004-11-03 ES ES10182018T patent/ES2400456T3/es not_active Expired - Lifetime
- 2004-11-03 EP EP10181974A patent/EP2261374B1/en not_active Expired - Lifetime
- 2004-11-03 PL PL10182056T patent/PL2261378T3/pl unknown
- 2004-11-03 CA CA2544848A patent/CA2544848C/en not_active Expired - Fee Related
2009
- 2009-02-17 US US12/378,558 patent/US20090264362A1/en not_active Abandoned
2010
- 2010-03-18 AU AU2010201046A patent/AU2010201046B2/en not_active Ceased
2012
- 2012-05-29 US US13/482,388 patent/US8598116B2/en not_active Expired - Fee Related
2013
- 2013-08-08 US US13/962,524 patent/US9056900B2/en not_active Expired - Lifetime
2015
- 2015-05-13 US US14/711,364 patent/US9725487B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP2261377B1 (en)	2013-10-02
EP2261376B1 (en)	2013-07-10
EP2261380B1 (en)	2013-07-17
EP2261378A2 (en)	2010-12-15
EP2261376A3 (en)	2011-02-23
AU2004288218A1 (en)	2005-05-19
US20090264362A1 (en)	2009-10-22
HK1152083A1 (en)	2012-02-17
DK2261378T3 (da)	2014-01-20
EP2261377A2 (en)	2010-12-15
DK2261377T3 (da)	2014-01-06
US9725487B2 (en)	2017-08-08
WO2005044992A3 (en)	2006-12-07
ES2425600T3 (es)	2013-10-16
AU2010201046B2 (en)	2013-06-27
EP2261378B1 (en)	2013-10-09
EP1692265B1 (en)	2011-08-03
EP2261376A2 (en)	2010-12-15
PT2261376E (pt)	2013-09-23
EP2261378A3 (en)	2011-06-15
US20120289458A1 (en)	2012-11-15
DK2261376T3 (da)	2013-10-07
JP2007514408A (ja)	2007-06-07
DK2261375T3 (da)	2013-04-22
DK1692265T3 (da)	2011-11-21
AU2004288218B2 (en)	2009-12-24
PL2261376T3 (pl)	2014-04-30
EP1692265A2 (en)	2006-08-23
PL1692265T3 (pl)	2011-12-30
ES2437858T3 (es)	2014-01-14
HK1152081A1 (en)	2012-02-17
HK1152086A1 (en)	2012-02-17
US9056900B2 (en)	2015-06-16
EP2261375A2 (en)	2010-12-15
EP1692265A4 (en)	2007-08-29
PT2261377E (pt)	2013-11-29
ES2435941T3 (es)	2013-12-26
EP2261374A2 (en)	2010-12-15
ATE518967T1 (de)	2011-08-15
US8598116B2 (en)	2013-12-03
PT2261378E (pt)	2013-12-09
ES2372633T3 (es)	2012-01-25
ES2427847T3 (es)	2013-11-04
US20060280754A1 (en)	2006-12-14
PL2261378T3 (pl)	2014-03-31
EP2261374B1 (en)	2012-06-06
EP2261374A3 (en)	2011-03-02
EP2261380A2 (en)	2010-12-15
PT1692265E (pt)	2011-10-11
US7491793B2 (en)	2009-02-17
EP2261377A3 (en)	2011-05-18
HK1152085A1 (en)	2012-02-17
EP2261375B1 (en)	2013-01-23
ES2400456T3 (es)	2013-04-10
HK1152084A1 (en)	2012-02-17
BRPI0416187A (pt)	2007-01-23
US20140045743A1 (en)	2014-02-13
US20150239940A1 (en)	2015-08-27
HK1152082A1 (en)	2012-02-17
CA2544848A1 (en)	2005-05-19
DK2261374T3 (da)	2012-09-10
PL2261377T3 (pl)	2014-03-31
EP2261380A3 (en)	2011-02-23
ES2392891T3 (es)	2012-12-14
EP2261375A3 (en)	2011-06-22
WO2005044992A2 (en)	2005-05-19
AU2010201046A1 (en)	2010-04-08
CA2544848C (en)	2015-12-29
JP5008398B2 (ja)	2012-08-22

Publication	Publication Date	Title
DK2261376T3 (da)	2013-10-07	Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA vira med klasse I membranfusogene indhyldningsproteiner
Alabi et al.	2012	High‐throughput sequence analysis of small RNA s in grapevine (V itis vinifera L.) affected by grapevine leafroll disease
Albarino et al.	2009	Efficient reverse genetics generation of infectious Junin viruses differing in glycoprotein processing
NZ598000A (en)	2013-10-25	Composition for treating hbv infection
NO20070194L (no)	2007-04-16	Fremgangsmater for behandling av hepatitt C
CY1114356T1 (el)	2016-04-13	Αναστολεις του ιου της ηπατιτιδας c
DK1644363T3 (da)	2012-05-29	Triheterocykliske forbindelser, sammensætninger og fremgangsmåder til behandling af cancer eller virussygdomme
EP1507791A4 (en)	2007-04-04	ANTISENSE ANTIVIRUS AGENTS AND METHOD FOR TREATING SSRNA VIRUS INFECTION
NO20071162L (no)	2007-04-17	Heterosykliske antivirale forbindelser
WO2005007805A3 (en)	2006-05-04	ANTISENSE ANTIVIRAL AGENT AND METHOD FOR TREATING ssRNA VIRAL INFECTION
ATE540116T1 (de)	2012-01-15	Antivirale antisense-verbindungen und verfahren zur behandlung von filovirus-infektionen
ATE494373T2 (de)	2011-01-15	Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle
WO2010055164A3 (en)	2010-07-08	Isoquinolone derivatives as inhibitors of plavivirus replication
WO2010047830A3 (en)	2010-07-01	Agents for hcv treatment
WO2007084435A3 (en)	2007-11-08	Methods for treating hepatitis c
J. Blake et al.	2012	RNA interference for viral infections
WO2010014248A3 (en)	2010-07-29	Antiviral activity of the protein scytovirin and methods of use
ATE505541T1 (de)	2011-04-15	Targeting von zwischenprodukten zur gegenstrangreplikation von einzelstrangigen viren durch rnai
EA200601218A1 (ru)	2006-12-29	Респираторно-синцитиальный вирус с перекрёстно компенсированным геномным дефицитом
Mega et al.	2020	Mutagenic analysis of Hazara nairovirus nontranslated regions during single-and multistep growth identifies both attenuating and functionally critical sequences for virus replication
EA202191220A1 (ru)	2021-07-29	НОВЫЕ МОЧЕВИНО-6,7-ДИГИДРО-4H-ПИРАЗОЛО[4,3-с]ПИРИДИНЫ, АКТИВНЫЕ ПРОТИВ ВИРУСА ГЕПАТИТА В (HBV)
WO2002074941A8 (de)	2002-10-24	Reportervirus mit heterologen hüllproteinen
TW200738626A (en)	2007-10-16	Methods for treating hepatitis C